Table of Content

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. Markets: Industry Outlook
1.1 Introduction
1.2 Market Trends
1.3 Epidemiology Analysis
1.4 Regulatory Framework
1.4.1 Legal Requirement and Framework in the U.S.
1.4.2 Legal Requirement and Framework in the E.U.
1.4.3 Legal Requirement and Framework in Asia-Pacific
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities

2. Global Rheumatoid Arthritis Market, by Drug Type, ($Million), 2023-2035
2.1 Overview
2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
2.3 Analgesics
2.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
2.5 Biologics
2.6 Others

3. Global Rheumatoid Arthritis Market, by Region, ($Million), 2023-2035
3.1 North America
3.1.1 Key Findings
3.1.2 Market Dynamics
3.1.3 Market Sizing and Forecast
3.1.3.1 North America Rheumatoid Arthritis Market, by Country
3.1.3.1.1 U.S.
3.1.3.1.2 Canada
3.2 Europe
3.2.1 Key Findings
3.2.2 Market Dynamics
3.2.3 Market Sizing and Forecast
3.2.3.1 Europe Rheumatoid Arthritis Market, by Country
3.2.3.1.1 Germany
3.2.3.1.2 U.K.
3.2.3.1.3 France
3.2.3.1.4 Italy
3.2.3.1.5 Spain
3.2.3.1.6 Rest-of-Europe
3.3 Asia-Pacific
3.3.1 Key Findings
3.3.2 Market Dynamics
3.3.3 Market Sizing and Forecast
3.3.3.1 Asia Pacific Rheumatoid Arthritis Market, by Country
3.3.3.1.1 China
3.3.3.1.2 Japan
3.3.3.1.3 India
3.3.3.1.4 South Korea
3.3.3.1.5 Australia
3.3.3.1.6 Rest-of- Asia-Pacific
3.4 Rest of the World
3.4.1 Key Findings
3.4.2 Market Dynamics
3.4.3 Market Sizing and Forecast

4. Global Rheumatoid Arthritis Market: Competitive Landscape and Company Profiles
4.1 Key Developments and Strategies
4.1.1 Mergers and Acquisitions
4.1.2 Synergistic Activities
4.1.3 Business Expansions and Funding
4.1.4 Product Launches and Approvals
4.1.5 Other Activities
4.2 Company Profiles
4.2.1 AbbVie, Inc.
4.2.1.1 Overview
4.2.1.2 Top Products / Product Portfolio
4.2.1.3 Top Competitors
4.2.1.4 Target Customers/End-Users
4.2.1.5 Key Personnel
4.2.1.6 Analyst View
4.2.2 Boehringer Ingelheim International GmbH
4.2.2.1 Overview
4.2.2.2 Top Products / Product Portfolio
4.2.2.3 Top Competitors
4.2.2.4 Target Customers/End-Users
4.2.2.5 Key Personnel
4.2.2.6 Analyst View
4.2.3 Novartis AG
4.2.3.1 Overview
4.2.3.2 Top Products / Product Portfolio
4.2.3.3 Top Competitors
4.2.3.4 Target Customers/End-Users
4.2.3.5 Key Personnel
4.2.3.6 Analyst View
4.2.4 Regeneron Pharmaceuticals, Inc.
4.2.4.1 Overview
4.2.4.2 Top Products / Product Portfolio
4.2.4.3 Top Competitors
4.2.4.4 Target Customers/End-Users
4.2.4.5 Key Personnel
4.2.4.6 Analyst View
4.2.5 Pfizer, Inc.
4.2.5.1 Overview
4.2.5.2 Top Products / Product Portfolio
4.2.5.3 Top Competitors
4.2.5.4 Target Customers/End-Users
4.2.5.5 Key Personnel
4.2.5.6 Analyst View
4.2.6 Bristol-Myers Squibb Company
4.2.6.1 Overview
4.2.6.2 Top Products / Product Portfolio
4.2.6.3 Top Competitors
4.2.6.4 Target Customers/End-Users
4.2.6.5 Key Personnel
4.2.6.6 Analyst View
4.2.7 F. Hoffmann-La Roche Ltd.
4.2.7.1 Overview
4.2.7.2 Top Products / Product Portfolio
4.2.7.3 Top Competitors
4.2.7.4 Target Customers/End-Users
4.2.7.5 Key Personnel
4.2.7.6 Analyst View
4.2.8 UCB S.A.
4.2.8.1 Overview
4.2.8.2 Top Products / Product Portfolio
4.2.8.3 Top Competitors
4.2.8.4 Target Customers/End-Users
4.2.8.5 Key Personnel
4.2.8.6 Analyst View
4.2.9 Johnson & Johnson
4.2.9.1 Overview
4.2.9.2 Top Products / Product Portfolio
4.2.9.3 Top Competitors
4.2.9.4 Target Customers/End-Users
4.2.9.5 Key Personnel
4.2.9.6 Analyst View
4.2.10 Amgen, Inc.
4.2.10.1 Overview
4.2.10.2 Top Products / Product Portfolio
4.2.10.3 Top Competitors
4.2.10.4 Target Customers/End-Users
4.2.10.5 Key Personnel
4.2.10.6 Analyst View
4.2.11 Eli Lilly and Company
4.2.11.1 Overview
4.2.11.2 Top Products / Product Portfolio
4.2.11.3 Top Competitors
4.2.11.4 Target Customers/End-Users
4.2.11.5 Key Personnel
4.2.11.6 Analyst View

5. Research Methodology

List of Figures
Figure: Global Rheumatoid Arthritis Market (by Region), $Million, 2024 and 2035
Figure: Global Rheumatoid Arthritis Market Key Trends, Analysis

List of Tables
Table: Global Rheumatoid Arthritis Market, Clinical Trial Analysis
Table: Global Rheumatoid Arthritis Market Dynamics, Impact Analysis
Table: Global Rheumatoid Arthritis Market (by Drug Type), $Million, 2023-2035
Table: Global Rheumatoid Arthritis Market (by Region), $Million, 2023-2035